Keepmoat starts last phase at former hospital
Work on the housebuilder’s £66m redevelopment of the Seacroft site in east Leeds has started, taking the project to almost 800 homes.
Billed as The Timeless development, the Seacroft scheme has seen the area undergo significant regeneration and investment as part of a wider Leeds City Council regeneration programme.
The scheme, being delivered by the housebuilder, forms part of a long-established partnership with Homes England to deliver new homes that have given new purpose to around five acres of brownfield land that once housed Seacroft Hospital.
The 758-home development has been phased over four stages, with the first three phases delivered in partnership with Strata.
Work on the final phase of the transformation has now begun and will create the final 72 mixed tenure homes to the development, four miles from Leeds city centre.
Chris Clingo, regional managing director at Keepmoat, Yorkshire West, said “We’re thrilled to be continuing delivery under the Leeds City Council partnership to deliver quality, sustainable homes for the latest phase of the Timeless Development.
The development is a brownfield priority for Leeds. Credit: via Lucky North
“The development forms part of a wider regeneration project in East Leeds which is aiming to provide significant opportunity for the city’s growth. It has been a privilege to watch the new communities begin to flourish and it’s extremely rewarding to hear positive feedback from residents and breathe new life into the Seacroft area.”
Andrew Macfarlane, project manager for Homes England, the government’s housing and regeneration agency, added: “We are pleased to see the start of the final phase of the Seacroft Hospital development, unlocking land for a further 72 new homes in Leeds.
“This final phase of development reflects the strong partnership work between Homes England and Keepmoat bringing new housing to an area where it is needed most.”
In a separate project at Seacroft, plans from Leeds Teaching Hospitals NHS Trust were recently approved for the Rob Burrow Centre for Motor Neurone Disease.
